0.86
-5.00%
Close of 5 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Miricor Enterprises Holdings
Its shares trade on HKEX under the ticker 1827.HK. It has been listed since 10 January 2017. In the fiscal year to 31 March 2026, it reported revenue of HK$362.4m and net income of HK$11.2m. At that date it held total assets of HK$423.7m and shareholders' equity of HK$158.3m.
Miricor Enterprises Holdings Ltd. engages in the provision of non-surgical medical aesthetic services and sale of skin care products under CosMax and Cospeutic brands. The company employs 334 full-time employees The company went IPO on 2017-01-10. The firm and its subsidiaries are principally engaged in the provision of a broad range of non-surgical medical aesthetic services by doctors and trained therapists with an aim to improve the appearance of our clients. The main business of the company includes provision of treatment services, provision of consultation services, prescription and dispensing of medical products, sale of skin care products, and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Discretionary
- Industry
- Diversified Consumer Services
- Listed since
- 10 Jan 2017
- Employees
- 334
- Website
- miricor.com ↗
Leadership
Pay as last reported
- Mrs. Ka Yee LaiExecutive Chairlady of the Board, Chief Executive Officer, since 2016HK$6.2m
- Mr. Tsz Leung HoExecutive DirectorHK$2.2m
- Dr. Ping-yan LamExecutive Director, since 2020HK$600,000
- Mr. Tai On LoCompany Secretary
- Mr. Fu Kwok ChengNon-Executive Independent DirectorHK$204,000
- Mr. Yuk Wo ChengNon-Executive Independent DirectorHK$204,000
- Mr. Wai Kwan LiNon-Executive Independent DirectorHK$204,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CosMax and Cospeutic brands drive strong market presence in Hong Kong's aesthetic services sector.
- 334 full-time employees support comprehensive service delivery across multiple locations.
- Non-surgical medical aesthetic services align with growing consumer demand for minimally invasive treatments.
Weaknesses
- Limited geographic expansion beyond Hong Kong restricts market reach and growth potential.
- Reliance on a single sector (Consumer Discretionary) increases vulnerability to market fluctuations.
- IPO in 2017 may indicate limited capital for aggressive expansion strategies.
Opportunities
- Expanding into neighboring Asian markets like Singapore and Thailand offers new revenue streams.
- Growing demand for non-surgical aesthetic treatments in the Asia-Pacific region presents opportunities.
- Increasing consumer interest in skin care products can boost sales of CosMax and Cospeutic lines.
Threats
- Intense competition from established players in Hong Kong's medical aesthetic industry.
- Regulatory changes in Hong Kong could impact service delivery and product sales.
- Economic downturns may reduce consumer spending on discretionary services like aesthetics.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.